Xeomin was FDA-approved in 2010 for the treatment of wrinkles. Like Botox, Dysport, and Jueveau, it is used to improve the appearance of frown lines between the eyebrows, around the eyes, and the forehead. The main difference is that it is the first neuromodulator that does not need to be refrigerated before use, which may simplify distribution. Xeomin is also has no additives, just botulinum toxin type A. This may mean that there is less risk of developing antibodies against Xeomin than other available neurotoxins. The body develops antibodies in response to a foreign invader and attacks. In theory, antibodies could prevent a neurotoxin from having its desired effects. The effects of Xeomin occur within one week, and the results last from three to six months, making it comparable to Botox/Dysport/Jueveau in terms of both onset and duration of action.